nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—OPRM1—epilepsy syndrome	0.507	0.721	CbGaD
Methylnaltrexone—CYP2D6—epilepsy syndrome	0.196	0.279	CbGaD
Methylnaltrexone—OPRM1—telencephalic ventricle—epilepsy syndrome	0.00651	0.187	CbGeAlD
Methylnaltrexone—OPRM1—ganglion—epilepsy syndrome	0.00405	0.116	CbGeAlD
Methylnaltrexone—OPRK1—forebrain—epilepsy syndrome	0.00239	0.0687	CbGeAlD
Methylnaltrexone—OPRM1—brainstem—epilepsy syndrome	0.00176	0.0506	CbGeAlD
Methylnaltrexone—OPRM1—forebrain—epilepsy syndrome	0.0017	0.0488	CbGeAlD
Methylnaltrexone—OPRM1—telencephalon—epilepsy syndrome	0.00156	0.0449	CbGeAlD
Methylnaltrexone—OPRK1—head—epilepsy syndrome	0.00137	0.0393	CbGeAlD
Methylnaltrexone—OPRK1—nervous system—epilepsy syndrome	0.0013	0.0373	CbGeAlD
Methylnaltrexone—OPRK1—central nervous system—epilepsy syndrome	0.00125	0.0359	CbGeAlD
Methylnaltrexone—CYP2D6—hindbrain—epilepsy syndrome	0.00123	0.0354	CbGeAlD
Methylnaltrexone—OPRK1—cerebellum—epilepsy syndrome	0.00122	0.0351	CbGeAlD
Methylnaltrexone—OPRM1—midbrain—epilepsy syndrome	0.00112	0.0323	CbGeAlD
Methylnaltrexone—OPRM1—spinal cord—epilepsy syndrome	0.0011	0.0315	CbGeAlD
Methylnaltrexone—Flatulence—Lacosamide—epilepsy syndrome	0.001	0.00684	CcSEcCtD
Methylnaltrexone—Injection site reaction—Pregabalin—epilepsy syndrome	0.001	0.00683	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Primidone—epilepsy syndrome	0.001	0.00682	CcSEcCtD
Methylnaltrexone—OPRK1—brain—epilepsy syndrome	0.000991	0.0285	CbGeAlD
Methylnaltrexone—OPRM1—head—epilepsy syndrome	0.000973	0.028	CbGeAlD
Methylnaltrexone—OPRM1—nervous system—epilepsy syndrome	0.000923	0.0265	CbGeAlD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Rufinamide—epilepsy syndrome	0.000918	0.00625	CcSEcCtD
Methylnaltrexone—OPRM1—central nervous system—epilepsy syndrome	0.000888	0.0255	CbGeAlD
Methylnaltrexone—Nervous system disorder—Rufinamide—epilepsy syndrome	0.000869	0.00592	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Lacosamide—epilepsy syndrome	0.000862	0.00587	CcSEcCtD
Methylnaltrexone—Skin disorder—Rufinamide—epilepsy syndrome	0.000861	0.00586	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Clobazam—epilepsy syndrome	0.000837	0.0057	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Trimethadione—epilepsy syndrome	0.000834	0.00568	CcSEcCtD
Methylnaltrexone—Erythema—Propofol—epilepsy syndrome	0.000819	0.00558	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Lacosamide—epilepsy syndrome	0.000816	0.00556	CcSEcCtD
Methylnaltrexone—Skin disorder—Lacosamide—epilepsy syndrome	0.000808	0.00551	CcSEcCtD
Methylnaltrexone—Abdominal pain—Trimethadione—epilepsy syndrome	0.000806	0.00549	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Lacosamide—epilepsy syndrome	0.000804	0.00548	CcSEcCtD
Methylnaltrexone—Erythema—Midazolam—epilepsy syndrome	0.000802	0.00546	CcSEcCtD
Methylnaltrexone—Dizziness—Amobarbital—epilepsy syndrome	0.000795	0.00542	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Clobazam—epilepsy syndrome	0.000792	0.0054	CcSEcCtD
Methylnaltrexone—Skin disorder—Clobazam—epilepsy syndrome	0.000784	0.00534	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Clobazam—epilepsy syndrome	0.000781	0.00532	CcSEcCtD
Methylnaltrexone—Pain—Phenobarbital—epilepsy syndrome	0.000772	0.00526	CcSEcCtD
Methylnaltrexone—Dizziness—Primidone—epilepsy syndrome	0.000766	0.00522	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Rufinamide—epilepsy syndrome	0.000765	0.00521	CcSEcCtD
Methylnaltrexone—Vomiting—Amobarbital—epilepsy syndrome	0.000765	0.00521	CcSEcCtD
Methylnaltrexone—Flatulence—Fosphenytoin—epilepsy syndrome	0.000753	0.00513	CcSEcCtD
Methylnaltrexone—Vomiting—Primidone—epilepsy syndrome	0.000737	0.00502	CcSEcCtD
Methylnaltrexone—Erythema—Diazepam—epilepsy syndrome	0.000733	0.00499	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Lacosamide—epilepsy syndrome	0.000718	0.00489	CcSEcCtD
Methylnaltrexone—Nausea—Amobarbital—epilepsy syndrome	0.000714	0.00487	CcSEcCtD
Methylnaltrexone—CYP2D6—brainstem—epilepsy syndrome	0.000706	0.0203	CbGeAlD
Methylnaltrexone—OPRM1—brain—epilepsy syndrome	0.000705	0.0203	CbGeAlD
Methylnaltrexone—Flatulence—Felbamate—epilepsy syndrome	0.000699	0.00476	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Clobazam—epilepsy syndrome	0.000697	0.00475	CcSEcCtD
Methylnaltrexone—Nausea—Primidone—epilepsy syndrome	0.000688	0.00469	CcSEcCtD
Methylnaltrexone—Flatulence—Zonisamide—epilepsy syndrome	0.000684	0.00466	CcSEcCtD
Methylnaltrexone—CYP2D6—forebrain—epilepsy syndrome	0.000681	0.0196	CbGeAlD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Midazolam—epilepsy syndrome	0.000678	0.00462	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Levetiracetam—epilepsy syndrome	0.000669	0.00456	CcSEcCtD
Methylnaltrexone—Oedema—Propofol—epilepsy syndrome	0.000669	0.00455	CcSEcCtD
Methylnaltrexone—Nalbuphine—OPRD1—epilepsy syndrome	0.00066	0.0768	CrCbGaD
Methylnaltrexone—Flatulence—Clonazepam—epilepsy syndrome	0.00066	0.00449	CcSEcCtD
Methylnaltrexone—Flatulence—Phenytoin—epilepsy syndrome	0.000655	0.00446	CcSEcCtD
Methylnaltrexone—Flatulence—Oxcarbazepine—epilepsy syndrome	0.000652	0.00444	CcSEcCtD
Methylnaltrexone—Vomiting—Trimethadione—epilepsy syndrome	0.000648	0.00442	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Propofol—epilepsy syndrome	0.000646	0.0044	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Midazolam—epilepsy syndrome	0.000641	0.00437	CcSEcCtD
Methylnaltrexone—Skin disorder—Midazolam—epilepsy syndrome	0.000635	0.00433	CcSEcCtD
Methylnaltrexone—Erythema—Carbamazepine—epilepsy syndrome	0.000635	0.00432	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Levetiracetam—epilepsy syndrome	0.000633	0.00432	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vigabatrin—epilepsy syndrome	0.00063	0.00429	CcSEcCtD
Methylnaltrexone—Skin disorder—Levetiracetam—epilepsy syndrome	0.000627	0.00427	CcSEcCtD
Methylnaltrexone—CYP2D6—telencephalon—epilepsy syndrome	0.000627	0.018	CbGeAlD
Methylnaltrexone—Gastrointestinal disorder—Acetazolamide—epilepsy syndrome	0.000621	0.00423	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Diazepam—epilepsy syndrome	0.00062	0.00422	CcSEcCtD
Methylnaltrexone—Erythema—Lamotrigine—epilepsy syndrome	0.000613	0.00418	CcSEcCtD
Methylnaltrexone—Oedema—Vigabatrin—epilepsy syndrome	0.000608	0.00414	CcSEcCtD
Methylnaltrexone—Diarrhoea—Rufinamide—epilepsy syndrome	0.000606	0.00413	CcSEcCtD
Methylnaltrexone—Nausea—Trimethadione—epilepsy syndrome	0.000606	0.00412	CcSEcCtD
Methylnaltrexone—Flatulence—Lamotrigine—epilepsy syndrome	0.000604	0.00412	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Fosphenytoin—epilepsy syndrome	0.000603	0.00411	CcSEcCtD
Methylnaltrexone—Dizziness—Phenobarbital—epilepsy syndrome	0.000597	0.00407	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vigabatrin—epilepsy syndrome	0.000596	0.00406	CcSEcCtD
Methylnaltrexone—Skin disorder—Vigabatrin—epilepsy syndrome	0.00059	0.00402	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Zonisamide—epilepsy syndrome	0.000587	0.004	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Diazepam—epilepsy syndrome	0.000587	0.004	CcSEcCtD
Methylnaltrexone—Dizziness—Rufinamide—epilepsy syndrome	0.000586	0.00399	CcSEcCtD
Methylnaltrexone—Skin disorder—Diazepam—epilepsy syndrome	0.000581	0.00396	CcSEcCtD
Methylnaltrexone—Oedema—Felbamate—epilepsy syndrome	0.000579	0.00394	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Diazepam—epilepsy syndrome	0.000578	0.00394	CcSEcCtD
Methylnaltrexone—Vomiting—Phenobarbital—epilepsy syndrome	0.000574	0.00391	CcSEcCtD
Methylnaltrexone—Pain—Propofol—epilepsy syndrome	0.000572	0.00389	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lacosamide—epilepsy syndrome	0.000569	0.00388	CcSEcCtD
Methylnaltrexone—Oedema—Zonisamide—epilepsy syndrome	0.000567	0.00386	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Clonazepam—epilepsy syndrome	0.000566	0.00385	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Midazolam—epilepsy syndrome	0.000565	0.00385	CcSEcCtD
Methylnaltrexone—Vomiting—Rufinamide—epilepsy syndrome	0.000563	0.00384	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Felbamate—epilepsy syndrome	0.00056	0.00381	CcSEcCtD
Methylnaltrexone—Pain—Midazolam—epilepsy syndrome	0.000559	0.00381	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Oxcarbazepine—epilepsy syndrome	0.000559	0.00381	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Levetiracetam—epilepsy syndrome	0.000558	0.0038	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Zonisamide—epilepsy syndrome	0.000556	0.00379	CcSEcCtD
Methylnaltrexone—Diarrhoea—Clobazam—epilepsy syndrome	0.000553	0.00376	CcSEcCtD
Methylnaltrexone—Pain—Levetiracetam—epilepsy syndrome	0.000552	0.00376	CcSEcCtD
Methylnaltrexone—Skin disorder—Zonisamide—epilepsy syndrome	0.000551	0.00375	CcSEcCtD
Methylnaltrexone—Dizziness—Lacosamide—epilepsy syndrome	0.00055	0.00375	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Zonisamide—epilepsy syndrome	0.000548	0.00373	CcSEcCtD
Methylnaltrexone—Oedema—Clonazepam—epilepsy syndrome	0.000546	0.00372	CcSEcCtD
Methylnaltrexone—Oxymorphone—OPRD1—epilepsy syndrome	0.000538	0.0626	CrCbGaD
Methylnaltrexone—Naltrexone—OPRD1—epilepsy syndrome	0.000538	0.0626	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Carbamazepine—epilepsy syndrome	0.000537	0.00366	CcSEcCtD
Methylnaltrexone—Nausea—Phenobarbital—epilepsy syndrome	0.000536	0.00365	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Clonazepam—epilepsy syndrome	0.000536	0.00365	CcSEcCtD
Methylnaltrexone—Dizziness—Clobazam—epilepsy syndrome	0.000534	0.00364	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Phenytoin—epilepsy syndrome	0.000532	0.00362	CcSEcCtD
Methylnaltrexone—Skin disorder—Clonazepam—epilepsy syndrome	0.000531	0.00361	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Oxcarbazepine—epilepsy syndrome	0.000529	0.00361	CcSEcCtD
Methylnaltrexone—Vomiting—Lacosamide—epilepsy syndrome	0.000529	0.0036	CcSEcCtD
Methylnaltrexone—Abdominal pain—Propofol—epilepsy syndrome	0.000529	0.0036	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Levetiracetam—epilepsy syndrome	0.000528	0.0036	CcSEcCtD
Methylnaltrexone—Nausea—Rufinamide—epilepsy syndrome	0.000526	0.00359	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vigabatrin—epilepsy syndrome	0.000525	0.00357	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Phenytoin—epilepsy syndrome	0.000525	0.00357	CcSEcCtD
Methylnaltrexone—Skin disorder—Oxcarbazepine—epilepsy syndrome	0.000524	0.00357	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Oxcarbazepine—epilepsy syndrome	0.000522	0.00355	CcSEcCtD
Methylnaltrexone—Pain—Vigabatrin—epilepsy syndrome	0.00052	0.00354	CcSEcCtD
Methylnaltrexone—Oedema—Carbamazepine—epilepsy syndrome	0.000518	0.00353	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Diazepam—epilepsy syndrome	0.000517	0.00352	CcSEcCtD
Methylnaltrexone—Vomiting—Clobazam—epilepsy syndrome	0.000513	0.0035	CcSEcCtD
Methylnaltrexone—Pain—Diazepam—epilepsy syndrome	0.000512	0.00349	CcSEcCtD
Methylnaltrexone—Abdominal pain—Levetiracetam—epilepsy syndrome	0.000511	0.00348	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Carbamazepine—epilepsy syndrome	0.000508	0.00346	CcSEcCtD
Methylnaltrexone—Nalbuphine—OPRM1—epilepsy syndrome	0.000505	0.0588	CrCbGaD
Methylnaltrexone—Skin disorder—Carbamazepine—epilepsy syndrome	0.000503	0.00343	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Carbamazepine—epilepsy syndrome	0.000501	0.00341	CcSEcCtD
Methylnaltrexone—Oedema—Lamotrigine—epilepsy syndrome	0.000501	0.00341	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vigabatrin—epilepsy syndrome	0.000497	0.00339	CcSEcCtD
Methylnaltrexone—Pain—Felbamate—epilepsy syndrome	0.000495	0.00337	CcSEcCtD
Methylnaltrexone—Nausea—Lacosamide—epilepsy syndrome	0.000494	0.00337	CcSEcCtD
Methylnaltrexone—Diarrhoea—Acetazolamide—epilepsy syndrome	0.000493	0.00335	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Lamotrigine—epilepsy syndrome	0.000491	0.00334	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Zonisamide—epilepsy syndrome	0.000489	0.00333	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Diazepam—epilepsy syndrome	0.000489	0.00333	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Lamotrigine—epilepsy syndrome	0.000484	0.0033	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vigabatrin—epilepsy syndrome	0.00048	0.00327	CcSEcCtD
Methylnaltrexone—Flatulence—Valproic Acid—epilepsy syndrome	0.00048	0.00327	CcSEcCtD
Methylnaltrexone—Nausea—Clobazam—epilepsy syndrome	0.00048	0.00327	CcSEcCtD
Methylnaltrexone—Dizziness—Acetazolamide—epilepsy syndrome	0.000476	0.00324	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Felbamate—epilepsy syndrome	0.000474	0.00323	CcSEcCtD
Methylnaltrexone—Abdominal pain—Diazepam—epilepsy syndrome	0.000473	0.00322	CcSEcCtD
Methylnaltrexone—Naloxone—SLCO1A2—epilepsy syndrome	0.000472	0.0549	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Clonazepam—epilepsy syndrome	0.000472	0.00321	CcSEcCtD
Methylnaltrexone—Hydrocodone—OPRD1—epilepsy syndrome	0.00047	0.0548	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	0.000468	0.00319	CcSEcCtD
Methylnaltrexone—Pain—Clonazepam—epilepsy syndrome	0.000467	0.00318	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	0.000466	0.00317	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Zonisamide—epilepsy syndrome	0.000463	0.00316	CcSEcCtD
Methylnaltrexone—Pain—Oxcarbazepine—epilepsy syndrome	0.000462	0.00314	CcSEcCtD
Methylnaltrexone—Abdominal pain—Felbamate—epilepsy syndrome	0.000458	0.00312	CcSEcCtD
Methylnaltrexone—Vomiting—Acetazolamide—epilepsy syndrome	0.000458	0.00312	CcSEcCtD
Methylnaltrexone—Diarrhoea—Propofol—epilepsy syndrome	0.000457	0.00312	CcSEcCtD
Methylnaltrexone—Abdominal pain—Zonisamide—epilepsy syndrome	0.000448	0.00305	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000447	0.00305	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Clonazepam—epilepsy syndrome	0.000447	0.00304	CcSEcCtD
Methylnaltrexone—Pain—Carbamazepine—epilepsy syndrome	0.000443	0.00302	CcSEcCtD
Methylnaltrexone—Dizziness—Propofol—epilepsy syndrome	0.000442	0.00301	CcSEcCtD
Methylnaltrexone—Diarrhoea—Levetiracetam—epilepsy syndrome	0.000442	0.00301	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Oxcarbazepine—epilepsy syndrome	0.000441	0.00301	CcSEcCtD
Methylnaltrexone—Flatulence—Pregabalin—epilepsy syndrome	0.000434	0.00296	CcSEcCtD
Methylnaltrexone—Dizziness—Midazolam—epilepsy syndrome	0.000433	0.00295	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	0.000432	0.00294	CcSEcCtD
Methylnaltrexone—Abdominal pain—Clonazepam—epilepsy syndrome	0.000432	0.00294	CcSEcCtD
Methylnaltrexone—Oxycodone—OPRD1—epilepsy syndrome	0.000429	0.05	CrCbGaD
Methylnaltrexone—Pain—Lamotrigine—epilepsy syndrome	0.000428	0.00292	CcSEcCtD
Methylnaltrexone—Nausea—Acetazolamide—epilepsy syndrome	0.000428	0.00291	CcSEcCtD
Methylnaltrexone—Dizziness—Levetiracetam—epilepsy syndrome	0.000427	0.00291	CcSEcCtD
Methylnaltrexone—Abdominal pain—Oxcarbazepine—epilepsy syndrome	0.000427	0.00291	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fosphenytoin—epilepsy syndrome	0.000427	0.00291	CcSEcCtD
Methylnaltrexone—Vomiting—Propofol—epilepsy syndrome	0.000425	0.0029	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	0.000424	0.00289	CcSEcCtD
Methylnaltrexone—Vomiting—Midazolam—epilepsy syndrome	0.000416	0.00283	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vigabatrin—epilepsy syndrome	0.000416	0.00283	CcSEcCtD
Methylnaltrexone—Dizziness—Fosphenytoin—epilepsy syndrome	0.000412	0.00281	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.000412	0.00281	CcSEcCtD
Methylnaltrexone—Oxymorphone—OPRM1—epilepsy syndrome	0.000412	0.0479	CrCbGaD
Methylnaltrexone—Naltrexone—OPRM1—epilepsy syndrome	0.000412	0.0479	CrCbGaD
Methylnaltrexone—Vomiting—Levetiracetam—epilepsy syndrome	0.000411	0.0028	CcSEcCtD
Methylnaltrexone—Abdominal pain—Carbamazepine—epilepsy syndrome	0.000409	0.00279	CcSEcCtD
Methylnaltrexone—Diarrhoea—Diazepam—epilepsy syndrome	0.000409	0.00279	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	0.000409	0.00279	CcSEcCtD
Methylnaltrexone—Erythema—Gabapentin—epilepsy syndrome	0.000404	0.00275	CcSEcCtD
Methylnaltrexone—Dizziness—Vigabatrin—epilepsy syndrome	0.000402	0.00274	CcSEcCtD
Methylnaltrexone—Flatulence—Gabapentin—epilepsy syndrome	0.000398	0.00271	CcSEcCtD
Methylnaltrexone—Oedema—Valproic Acid—epilepsy syndrome	0.000398	0.00271	CcSEcCtD
Methylnaltrexone—Nausea—Propofol—epilepsy syndrome	0.000397	0.00271	CcSEcCtD
Methylnaltrexone—Vomiting—Fosphenytoin—epilepsy syndrome	0.000396	0.0027	CcSEcCtD
Methylnaltrexone—Diarrhoea—Felbamate—epilepsy syndrome	0.000396	0.0027	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lamotrigine—epilepsy syndrome	0.000396	0.0027	CcSEcCtD
Methylnaltrexone—Dizziness—Diazepam—epilepsy syndrome	0.000396	0.00269	CcSEcCtD
Methylnaltrexone—Buprenorphine—OPRD1—epilepsy syndrome	0.000395	0.046	CrCbGaD
Methylnaltrexone—Naloxone—OPRD1—epilepsy syndrome	0.000393	0.0457	CrCbGaD
Methylnaltrexone—CYP2D6—head—epilepsy syndrome	0.00039	0.0112	CbGeAlD
Methylnaltrexone—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.00039	0.00266	CcSEcCtD
Methylnaltrexone—Hydromorphone—OPRD1—epilepsy syndrome	0.00039	0.0454	CrCbGaD
Methylnaltrexone—Nausea—Midazolam—epilepsy syndrome	0.000389	0.00265	CcSEcCtD
Methylnaltrexone—Diarrhoea—Zonisamide—epilepsy syndrome	0.000388	0.00264	CcSEcCtD
Methylnaltrexone—Vomiting—Vigabatrin—epilepsy syndrome	0.000386	0.00263	CcSEcCtD
Methylnaltrexone—Skin disorder—Valproic Acid—epilepsy syndrome	0.000386	0.00263	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Valproic Acid—epilepsy syndrome	0.000385	0.00262	CcSEcCtD
Methylnaltrexone—Nausea—Levetiracetam—epilepsy syndrome	0.000384	0.00261	CcSEcCtD
Methylnaltrexone—Dizziness—Felbamate—epilepsy syndrome	0.000383	0.00261	CcSEcCtD
Methylnaltrexone—Vomiting—Diazepam—epilepsy syndrome	0.00038	0.00259	CcSEcCtD
Methylnaltrexone—Dizziness—Zonisamide—epilepsy syndrome	0.000375	0.00255	CcSEcCtD
Methylnaltrexone—Diarrhoea—Clonazepam—epilepsy syndrome	0.000374	0.00255	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000373	0.00254	CcSEcCtD
Methylnaltrexone—Diarrhoea—Phenytoin—epilepsy syndrome	0.000371	0.00253	CcSEcCtD
Methylnaltrexone—Nausea—Fosphenytoin—epilepsy syndrome	0.00037	0.00252	CcSEcCtD
Methylnaltrexone—CYP2D6—nervous system—epilepsy syndrome	0.00037	0.0106	CbGeAlD
Methylnaltrexone—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000369	0.00252	CcSEcCtD
Methylnaltrexone—Vomiting—Felbamate—epilepsy syndrome	0.000368	0.00251	CcSEcCtD
Methylnaltrexone—Dizziness—Clonazepam—epilepsy syndrome	0.000361	0.00246	CcSEcCtD
Methylnaltrexone—Nausea—Vigabatrin—epilepsy syndrome	0.000361	0.00246	CcSEcCtD
Methylnaltrexone—Vomiting—Zonisamide—epilepsy syndrome	0.00036	0.00245	CcSEcCtD
Methylnaltrexone—Hydrocodone—OPRM1—epilepsy syndrome	0.00036	0.0419	CrCbGaD
Methylnaltrexone—Oedema—Pregabalin—epilepsy syndrome	0.00036	0.00245	CcSEcCtD
Methylnaltrexone—Dizziness—Phenytoin—epilepsy syndrome	0.000359	0.00244	CcSEcCtD
Methylnaltrexone—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000357	0.00243	CcSEcCtD
Methylnaltrexone—CYP2D6—central nervous system—epilepsy syndrome	0.000356	0.0102	CbGeAlD
Methylnaltrexone—Nausea—Diazepam—epilepsy syndrome	0.000355	0.00242	CcSEcCtD
Methylnaltrexone—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000354	0.00241	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000353	0.0024	CcSEcCtD
Methylnaltrexone—Skin disorder—Pregabalin—epilepsy syndrome	0.000349	0.00238	CcSEcCtD
Methylnaltrexone—CYP2D6—cerebellum—epilepsy syndrome	0.000348	0.01	CbGeAlD
Methylnaltrexone—Hyperhidrosis—Pregabalin—epilepsy syndrome	0.000348	0.00237	CcSEcCtD
Methylnaltrexone—Vomiting—Clonazepam—epilepsy syndrome	0.000347	0.00237	CcSEcCtD
Methylnaltrexone—Vomiting—Phenytoin—epilepsy syndrome	0.000345	0.00235	CcSEcCtD
Methylnaltrexone—Nausea—Felbamate—epilepsy syndrome	0.000344	0.00234	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000343	0.00234	CcSEcCtD
Methylnaltrexone—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000343	0.00234	CcSEcCtD
Methylnaltrexone—Dizziness—Carbamazepine—epilepsy syndrome	0.000343	0.00233	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000342	0.00233	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000342	0.00233	CcSEcCtD
Methylnaltrexone—Pain—Valproic Acid—epilepsy syndrome	0.00034	0.00232	CcSEcCtD
Methylnaltrexone—Erythema—Topiramate—epilepsy syndrome	0.00034	0.00232	CcSEcCtD
Methylnaltrexone—Nausea—Zonisamide—epilepsy syndrome	0.000337	0.00229	CcSEcCtD
Methylnaltrexone—Flatulence—Topiramate—epilepsy syndrome	0.000335	0.00228	CcSEcCtD
Methylnaltrexone—Dizziness—Lamotrigine—epilepsy syndrome	0.000331	0.00225	CcSEcCtD
Methylnaltrexone—Oedema—Gabapentin—epilepsy syndrome	0.00033	0.00225	CcSEcCtD
Methylnaltrexone—Vomiting—Carbamazepine—epilepsy syndrome	0.000329	0.00224	CcSEcCtD
Methylnaltrexone—Oxycodone—OPRM1—epilepsy syndrome	0.000328	0.0382	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	0.000325	0.00222	CcSEcCtD
Methylnaltrexone—Nausea—Clonazepam—epilepsy syndrome	0.000324	0.00221	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000323	0.0022	CcSEcCtD
Methylnaltrexone—Nausea—Phenytoin—epilepsy syndrome	0.000322	0.0022	CcSEcCtD
Methylnaltrexone—Nausea—Oxcarbazepine—epilepsy syndrome	0.000321	0.00218	CcSEcCtD
Methylnaltrexone—Skin disorder—Gabapentin—epilepsy syndrome	0.00032	0.00218	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gabapentin—epilepsy syndrome	0.000319	0.00217	CcSEcCtD
Methylnaltrexone—Vomiting—Lamotrigine—epilepsy syndrome	0.000318	0.00217	CcSEcCtD
Methylnaltrexone—Abdominal pain—Valproic Acid—epilepsy syndrome	0.000314	0.00214	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.00031	0.00211	CcSEcCtD
Methylnaltrexone—Nausea—Carbamazepine—epilepsy syndrome	0.000308	0.0021	CcSEcCtD
Methylnaltrexone—Pain—Pregabalin—epilepsy syndrome	0.000308	0.00209	CcSEcCtD
Methylnaltrexone—Buprenorphine—OPRM1—epilepsy syndrome	0.000303	0.0352	CrCbGaD
Methylnaltrexone—Naloxone—OPRM1—epilepsy syndrome	0.0003	0.035	CrCbGaD
Methylnaltrexone—Hydromorphone—OPRM1—epilepsy syndrome	0.000298	0.0347	CrCbGaD
Methylnaltrexone—Nausea—Lamotrigine—epilepsy syndrome	0.000297	0.00203	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pregabalin—epilepsy syndrome	0.000294	0.002	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000287	0.00196	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000285	0.00194	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pregabalin—epilepsy syndrome	0.000284	0.00194	CcSEcCtD
Methylnaltrexone—CYP2D6—brain—epilepsy syndrome	0.000283	0.00813	CbGeAlD
Methylnaltrexone—Pain—Gabapentin—epilepsy syndrome	0.000282	0.00192	CcSEcCtD
Methylnaltrexone—Oedema—Topiramate—epilepsy syndrome	0.000277	0.00189	CcSEcCtD
Methylnaltrexone—Diarrhoea—Valproic Acid—epilepsy syndrome	0.000272	0.00185	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Topiramate—epilepsy syndrome	0.000272	0.00185	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Gabapentin—epilepsy syndrome	0.00027	0.00184	CcSEcCtD
Methylnaltrexone—Skin disorder—Topiramate—epilepsy syndrome	0.000269	0.00184	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Topiramate—epilepsy syndrome	0.000268	0.00183	CcSEcCtD
Methylnaltrexone—Dizziness—Valproic Acid—epilepsy syndrome	0.000263	0.00179	CcSEcCtD
Methylnaltrexone—Abdominal pain—Gabapentin—epilepsy syndrome	0.000261	0.00178	CcSEcCtD
Methylnaltrexone—Vomiting—Valproic Acid—epilepsy syndrome	0.000253	0.00172	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pregabalin—epilepsy syndrome	0.000246	0.00168	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Topiramate—epilepsy syndrome	0.00024	0.00163	CcSEcCtD
Methylnaltrexone—Dizziness—Pregabalin—epilepsy syndrome	0.000238	0.00162	CcSEcCtD
Methylnaltrexone—Pain—Topiramate—epilepsy syndrome	0.000237	0.00162	CcSEcCtD
Methylnaltrexone—Nausea—Valproic Acid—epilepsy syndrome	0.000236	0.00161	CcSEcCtD
Methylnaltrexone—Vomiting—Pregabalin—epilepsy syndrome	0.000229	0.00156	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Topiramate—epilepsy syndrome	0.000227	0.00155	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gabapentin—epilepsy syndrome	0.000226	0.00154	CcSEcCtD
Methylnaltrexone—Abdominal pain—Topiramate—epilepsy syndrome	0.000219	0.00149	CcSEcCtD
Methylnaltrexone—Dizziness—Gabapentin—epilepsy syndrome	0.000218	0.00149	CcSEcCtD
Methylnaltrexone—Nausea—Pregabalin—epilepsy syndrome	0.000214	0.00146	CcSEcCtD
Methylnaltrexone—Vomiting—Gabapentin—epilepsy syndrome	0.00021	0.00143	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCG2—epilepsy syndrome	0.000201	0.0234	CrCbGaD
Methylnaltrexone—Nausea—Gabapentin—epilepsy syndrome	0.000196	0.00133	CcSEcCtD
Methylnaltrexone—Diarrhoea—Topiramate—epilepsy syndrome	0.00019	0.00129	CcSEcCtD
Methylnaltrexone—Dizziness—Topiramate—epilepsy syndrome	0.000183	0.00125	CcSEcCtD
Methylnaltrexone—Vomiting—Topiramate—epilepsy syndrome	0.000176	0.0012	CcSEcCtD
Methylnaltrexone—Nausea—Topiramate—epilepsy syndrome	0.000165	0.00112	CcSEcCtD
Methylnaltrexone—Oxymorphone—CYP2D6—epilepsy syndrome	0.000159	0.0186	CrCbGaD
Methylnaltrexone—Buprenorphine—CYP2C19—epilepsy syndrome	0.000158	0.0184	CrCbGaD
Methylnaltrexone—Hydrocodone—CYP2D6—epilepsy syndrome	0.000139	0.0162	CrCbGaD
Methylnaltrexone—Oxycodone—CYP2D6—epilepsy syndrome	0.000127	0.0148	CrCbGaD
Methylnaltrexone—Buprenorphine—CYP2D6—epilepsy syndrome	0.000117	0.0136	CrCbGaD
Methylnaltrexone—Hydromorphone—CYP2D6—epilepsy syndrome	0.000115	0.0134	CrCbGaD
Methylnaltrexone—Naltrexone—ABCB1—epilepsy syndrome	0.000114	0.0133	CrCbGaD
Methylnaltrexone—Naloxone—ALB—epilepsy syndrome	8.7e-05	0.0101	CrCbGaD
Methylnaltrexone—Buprenorphine—ABCB1—epilepsy syndrome	8.37e-05	0.00974	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—epilepsy syndrome	8.31e-05	0.00967	CrCbGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM3—epilepsy syndrome	3.67e-05	0.000346	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM4—epilepsy syndrome	3.67e-05	0.000346	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DUSP4—epilepsy syndrome	3.61e-05	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SSTR2—epilepsy syndrome	3.61e-05	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL12—epilepsy syndrome	3.6e-05	0.000339	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—BDKRB2—epilepsy syndrome	3.6e-05	0.000339	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HBEGF—epilepsy syndrome	3.59e-05	0.000338	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CDC42—epilepsy syndrome	3.54e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GAL—epilepsy syndrome	3.54e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GFAP—epilepsy syndrome	3.54e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR1—epilepsy syndrome	3.53e-05	0.000333	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT3—epilepsy syndrome	3.53e-05	0.000332	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PLCB1—epilepsy syndrome	3.52e-05	0.000331	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRM5—epilepsy syndrome	3.5e-05	0.00033	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP2—epilepsy syndrome	3.5e-05	0.00033	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CHRM3—epilepsy syndrome	3.5e-05	0.00033	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM8—epilepsy syndrome	3.48e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PGF—epilepsy syndrome	3.48e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SST—epilepsy syndrome	3.47e-05	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR2—epilepsy syndrome	3.47e-05	0.000327	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PNPO—epilepsy syndrome	3.45e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GAMT—epilepsy syndrome	3.45e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NHLRC1—epilepsy syndrome	3.45e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EPM2A—epilepsy syndrome	3.45e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR7—epilepsy syndrome	3.44e-05	0.000324	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AVP—epilepsy syndrome	3.43e-05	0.000323	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—POMC—epilepsy syndrome	3.41e-05	0.000321	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRA2A—epilepsy syndrome	3.4e-05	0.00032	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CX3CR1—epilepsy syndrome	3.36e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL2—epilepsy syndrome	3.34e-05	0.000314	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—OPRD1—epilepsy syndrome	3.32e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNAO1—epilepsy syndrome	3.32e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BDKRB1—epilepsy syndrome	3.29e-05	0.00031	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CX3CL1—epilepsy syndrome	3.29e-05	0.00031	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CHRM2—epilepsy syndrome	3.29e-05	0.00031	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT3—epilepsy syndrome	3.28e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL12—epilepsy syndrome	3.27e-05	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—BDKRB2—epilepsy syndrome	3.27e-05	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CDC42—epilepsy syndrome	3.22e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR1—epilepsy syndrome	3.21e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CA4—epilepsy syndrome	3.21e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—QDPR—epilepsy syndrome	3.21e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GABBR1—epilepsy syndrome	3.2e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—POMC—epilepsy syndrome	3.2e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PLCB1—epilepsy syndrome	3.19e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CHRM1—epilepsy syndrome	3.19e-05	0.0003	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDYN—epilepsy syndrome	3.19e-05	0.0003	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR7—epilepsy syndrome	3.19e-05	0.0003	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM1—epilepsy syndrome	3.19e-05	0.0003	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR7—epilepsy syndrome	3.13e-05	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AVP—epilepsy syndrome	3.12e-05	0.000293	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRH3—epilepsy syndrome	3.07e-05	0.000289	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HBEGF—epilepsy syndrome	3.04e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—OPRM1—epilepsy syndrome	3.02e-05	0.000285	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COX3—epilepsy syndrome	3.01e-05	0.000284	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CDC42—epilepsy syndrome	3e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GAL—epilepsy syndrome	2.99e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GFAP—epilepsy syndrome	2.99e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT3—epilepsy syndrome	2.98e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP2—epilepsy syndrome	2.96e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CHRM3—epilepsy syndrome	2.96e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM5—epilepsy syndrome	2.96e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR5—epilepsy syndrome	2.92e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AVP—epilepsy syndrome	2.9e-05	0.000273	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—KCNB1—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CACNA2D2—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLCO1A2—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PFKL—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC6A8—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR3—epilepsy syndrome	2.86e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2A—epilepsy syndrome	2.85e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CX3CR1—epilepsy syndrome	2.84e-05	0.000267	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CX3CL1—epilepsy syndrome	2.78e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CHRM2—epilepsy syndrome	2.78e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BDKRB1—epilepsy syndrome	2.78e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NPY—epilepsy syndrome	2.78e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ATP2A2—epilepsy syndrome	2.78e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CDC42—epilepsy syndrome	2.72e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AGT—epilepsy syndrome	2.71e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GABBR1—epilepsy syndrome	2.71e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—OXT—epilepsy syndrome	2.69e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL2—epilepsy syndrome	2.69e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HSPB1—epilepsy syndrome	2.69e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CRH—epilepsy syndrome	2.69e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL3—epilepsy syndrome	2.69e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR5—epilepsy syndrome	2.65e-05	0.000249	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AVP—epilepsy syndrome	2.63e-05	0.000248	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UPB1—epilepsy syndrome	2.61e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ATIC—epilepsy syndrome	2.61e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NEU1—epilepsy syndrome	2.61e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRH3—epilepsy syndrome	2.6e-05	0.000245	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2A—epilepsy syndrome	2.59e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD17B4—epilepsy syndrome	2.52e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.5e-05	0.000236	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TSC1—epilepsy syndrome	2.5e-05	0.000235	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTK2B—epilepsy syndrome	2.5e-05	0.000235	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR5—epilepsy syndrome	2.47e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AGT—epilepsy syndrome	2.46e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GBE1—epilepsy syndrome	2.43e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPP1R3C—epilepsy syndrome	2.43e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR2—epilepsy syndrome	2.43e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NTRK2—epilepsy syndrome	2.43e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SST—epilepsy syndrome	2.43e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR3—epilepsy syndrome	2.41e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2A—epilepsy syndrome	2.41e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DUSP6—epilepsy syndrome	2.41e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRA2A—epilepsy syndrome	2.38e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLAT—epilepsy syndrome	2.37e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NPY—epilepsy syndrome	2.35e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ATP2A2—epilepsy syndrome	2.35e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AGT—epilepsy syndrome	2.29e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ASAH1—epilepsy syndrome	2.28e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL12—epilepsy syndrome	2.28e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BDKRB2—epilepsy syndrome	2.28e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—POMC—epilepsy syndrome	2.28e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PRKCB—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CRH—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL3—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HSPB1—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL2—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—OXT—epilepsy syndrome	2.27e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6ST—epilepsy syndrome	2.26e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUNB—epilepsy syndrome	2.24e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR1—epilepsy syndrome	2.24e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR5—epilepsy syndrome	2.24e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLCB1—epilepsy syndrome	2.23e-05	0.00021	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STXBP1—epilepsy syndrome	2.22e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—epilepsy syndrome	2.19e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR7—epilepsy syndrome	2.19e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NT5E—epilepsy syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALAD—epilepsy syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HBEGF—epilepsy syndrome	2.12e-05	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.12e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TSC1—epilepsy syndrome	2.11e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTK2B—epilepsy syndrome	2.11e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT3—epilepsy syndrome	2.08e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGT—epilepsy syndrome	2.08e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—epilepsy syndrome	2.07e-05	0.000195	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	2.07e-05	0.000195	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	2.07e-05	0.000195	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR2—epilepsy syndrome	2.05e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NTRK2—epilepsy syndrome	2.05e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SST—epilepsy syndrome	2.05e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADAM10—epilepsy syndrome	2.04e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DUSP6—epilepsy syndrome	2.03e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—epilepsy syndrome	2.03e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	2.02e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRA2A—epilepsy syndrome	2.01e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLAT—epilepsy syndrome	2e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADSL—epilepsy syndrome	1.98e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GLUL—epilepsy syndrome	1.94e-05	0.000183	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BDKRB2—epilepsy syndrome	1.93e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL12—epilepsy syndrome	1.93e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—epilepsy syndrome	1.93e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—S100B—epilepsy syndrome	1.92e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCB—epilepsy syndrome	1.92e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6ST—epilepsy syndrome	1.91e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	1.91e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS3—epilepsy syndrome	1.91e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDC42—epilepsy syndrome	1.9e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR1—epilepsy syndrome	1.89e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUNB—epilepsy syndrome	1.89e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLCB1—epilepsy syndrome	1.89e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR7—epilepsy syndrome	1.85e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AVP—epilepsy syndrome	1.84e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HBEGF—epilepsy syndrome	1.79e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	1.78e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT3—epilepsy syndrome	1.76e-05	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—epilepsy syndrome	1.75e-05	0.000165	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—epilepsy syndrome	1.74e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AQP1—epilepsy syndrome	1.73e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADAM10—epilepsy syndrome	1.72e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—epilepsy syndrome	1.71e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FYN—epilepsy syndrome	1.69e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—H2AFX—epilepsy syndrome	1.69e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MEF2C—epilepsy syndrome	1.68e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.63e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—S100B—epilepsy syndrome	1.63e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS3—epilepsy syndrome	1.61e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NGF—epilepsy syndrome	1.61e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDC42—epilepsy syndrome	1.61e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	1.57e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	1.57e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR5—epilepsy syndrome	1.56e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AVP—epilepsy syndrome	1.56e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—epilepsy syndrome	1.53e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—epilepsy syndrome	1.47e-05	0.000139	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TSC2—epilepsy syndrome	1.45e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGT—epilepsy syndrome	1.45e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FYN—epilepsy syndrome	1.43e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—H2AFX—epilepsy syndrome	1.43e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—epilepsy syndrome	1.42e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MEF2C—epilepsy syndrome	1.42e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—epilepsy syndrome	1.39e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.38e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NGF—epilepsy syndrome	1.36e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCB—epilepsy syndrome	1.34e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6ST—epilepsy syndrome	1.34e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR5—epilepsy syndrome	1.32e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—epilepsy syndrome	1.29e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.28e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.24e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.24e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TSC2—epilepsy syndrome	1.23e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGT—epilepsy syndrome	1.23e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—epilepsy syndrome	1.22e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—epilepsy syndrome	1.2e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—epilepsy syndrome	1.2e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—epilepsy syndrome	1.18e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCB—epilepsy syndrome	1.13e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6ST—epilepsy syndrome	1.13e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—epilepsy syndrome	1.08e-05	0.000102	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.06e-05	0.0001	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.06e-05	9.96e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—epilepsy syndrome	1.03e-05	9.74e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—epilepsy syndrome	1.01e-05	9.53e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.01e-05	9.5e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RELA—epilepsy syndrome	1e-05	9.46e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	9.98e-06	9.4e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TH—epilepsy syndrome	9.94e-06	9.36e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTOR—epilepsy syndrome	9.85e-06	9.27e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—epilepsy syndrome	9.14e-06	8.61e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—epilepsy syndrome	9.14e-06	8.61e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—epilepsy syndrome	9.06e-06	8.53e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUN—epilepsy syndrome	8.8e-06	8.28e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—epilepsy syndrome	8.56e-06	8.06e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RELA—epilepsy syndrome	8.49e-06	7.99e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTOR—epilepsy syndrome	8.32e-06	7.84e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—epilepsy syndrome	8.3e-06	7.82e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	8.3e-06	7.82e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAT—epilepsy syndrome	8.19e-06	7.71e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	7.96e-06	7.5e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—epilepsy syndrome	7.89e-06	7.43e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	7.72e-06	7.28e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—epilepsy syndrome	7.68e-06	7.24e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—epilepsy syndrome	7.65e-06	7.21e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUN—epilepsy syndrome	7.43e-06	7e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—epilepsy syndrome	7.4e-06	6.97e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—epilepsy syndrome	7.23e-06	6.81e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—epilepsy syndrome	7.01e-06	6.61e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—epilepsy syndrome	6.67e-06	6.28e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—epilepsy syndrome	6.49e-06	6.12e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGT—epilepsy syndrome	6.49e-06	6.11e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—epilepsy syndrome	6.36e-06	5.99e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—epilepsy syndrome	5.47e-06	5.15e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—epilepsy syndrome	4.98e-06	4.69e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—epilepsy syndrome	4.9e-06	4.62e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	4.36e-06	4.11e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—epilepsy syndrome	4.14e-06	3.9e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—epilepsy syndrome	2.19e-06	2.06e-05	CbGpPWpGaD
